Tandem Diabetes Care, Inc. - Common Stock (TNDM)
16.91
-1.08 (-6.00%)
NASDAQ · Last Trade: Nov 6th, 5:57 PM EST
News & Press Releases
What Tandem Diabetes Care (TNDM) Said on Its Q3 Earnings Callmarketbeat.com
Tandem Diabetes Care (NASDAQ:TNDM) reported 14% revenue growth in the third quarter of 2026, as higher pump shipments, pharmacy pricing and international sales helped lift gross margin. The company also announced a CEO transition and signaled that a slower-than-expected shift to pharmacy distributio
Via MarketBeat · November 6, 2026
Tandem (TNDM) Q3 2026 Earnings Call Transcriptfool.com
Sheridan steps down as CEO while Mobi Tubeless nears FDA clearance
Via The Motley Fool · November 6, 2026
TNDM Q3 2026 deep dive: business model transition, product launches, and leadership change
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 13.8% year ...
Via StockStory · November 6, 2026
Tandem Diabetes Care (NASDAQ:TNDM) Q3 2026 Beat Lifts Stock on Margin Expansion Despite Soft Q4 Guidancechartmill.com
Via Chartmill · November 5, 2026
Tandem Diabetes (NASDAQ:TNDM) reports upbeat Q3 2026, stock soars
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q3 2026 results topping the market’s revenue expectations, with revenue up 13.8% year...
Via StockStory · November 5, 2026
Tandem Diabetes Care Names Jeannette Bankes as President and Chief Executive Officer
Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (“Tandem” or the “Company”), a global diabetes technology company, today announced the appointment of Jeannette Bankes as president and chief executive officer (“CEO”), and a member of its Board of Directors, effective November 16, 2026. Ms. Bankes will succeed John Sheridan, who will retire at the end of 2026 after more than a decade of service to Tandem, as part of a planned leadership transition.
By Tandem Diabetes Care, Inc. · Via Business Wire · November 5, 2026
Tandem Diabetes Care Announces Third Quarter 2026 Financial Results
Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2026.
By Tandem Diabetes Care, Inc. · Via Business Wire · November 5, 2026
Tandem Diabetes (TNDM) reports earnings tomorrow: what to expect
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) will be reporting earnings this Thursday afternoon. Here’s what investors should know. Tandem ...
Via StockStory · November 3, 2026
3 of Wall Street’s favorite stocks that concern us
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
Via StockStory · November 1, 2026
Tandem Diabetes Care Announces Upcoming Conference Presentations
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences:
By Tandem Diabetes Care, Inc. · Via Business Wire · October 30, 2026
3 Russell 2000 stocks that fall short
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ...
Via StockStory · October 28, 2026
Diabetes Cell Therapy Enters a New Era as Billion-Dollar Market Opportunity Takes Shape
From Insulin Management To Cell Replacement: The Diabetes Revolution Is Accelerating New York, NY – October 7, 2026 – Diabetes cell therapy is moving into a very different phase. For years, the idea of replacing damaged or lost insulin-producing cells sounded more like a long-term scientific goal than a practical treatment strategy. That is […]
Via FinancialNewsMedia · October 7, 2026
Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2026 results after the financial markets close on Thursday, November 5, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2026 financial and operating results.
By Tandem Diabetes Care, Inc. · Via Business Wire · October 1, 2026
Q2 Earnings Highlights: Tandem Diabetes (NASDAQ:TNDM) Vs The Rest Of The Healthcare Technology Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via StockStory · September 29, 2026
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world’s smallest, durable automated insulin delivery system for people living with diabetes,1 is now available in 12 countries outside the United States. The company is now taking orders and shipping to eligible customers in Belgium, the Czech Republic, Denmark, Finland, Germany, Israel, Italy, Luxembourg, Spain, Sweden, Switzerland, and the United Kingdom.
By Tandem Diabetes Care, Inc. · Via Business Wire · September 28, 2026
Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid S...
Via StockStory · September 23, 2026
3 Cash-Burning Stocks with Questionable Fundamentals
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them...
Via StockStory · September 18, 2026
3 Reasons TNDM is Risky and 1 Stock to Buy Instead
Over the last six months, Tandem Diabetes’s shares have sunk to $22.45, producing a disappointing 13.7% loss - a stark contrast to the S&P 500’s 10.5% gain. ...
Via StockStory · August 25, 2026
Tandem Diabetes Care Maps Growth Plan With Pharmacy Shift and Tubeless Mobimarketbeat.com
Tandem Diabetes Care (NASDAQ:TNDM) highlighted its plans to expand insulin pump adoption through a shift to pharmacy distribution in the U.S., direct sales in additional international markets and upcoming product launches, including a tubeless version of its Tandem Mobi pump.
Speaking at Canaccord’
Via MarketBeat · August 18, 2026
Tandem Diabetes (TNDM) Q2 2026 Earnings Call Transcriptfool.com
Pump shipments surged 10% as pharmacy adoption accelerated.
Via The Motley Fool · August 13, 2026
5 Must-Read Analyst Questions From Tandem Diabetes’s Q2 Earnings Call
Tandem Diabetes met Wall Street’s revenue and profit expectations in Q2, but the market responded negatively, likely reflecting investor caution around the p...
Via StockStory · August 13, 2026
Why Tandem Diabetes (TNDM) Stock Is Trading Up Today
What Happened? Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) jumped 18.2% in the afternoon session after the company reported seco...
Via StockStory · August 7, 2026
Tandem Diabetes Care Q2 Earnings Call Highlightsmarketbeat.com
Tandem Diabetes Care (NASDAQ:TNDM) reported second-quarter results that included record sales, pump shipments and gross margin for a second quarter, while management highlighted early progress in its transition to pharmacy-channel reimbursement and continued development of new insulin-delivery techn
Via MarketBeat · August 7, 2026
TNDM Q2 Deep Dive: Pharmacy Channel Gains and Pipeline Execution Amid Margin Recovery
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.8% year on year to $254.6...
Via StockStory · August 7, 2026
Tandem Diabetes’s (NASDAQ:TNDM) Q2 CY2026 Earnings Results: Revenue In Line With Expectations
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.8% year on year to $254.6...
Via StockStory · August 6, 2026